Assessing the Role of Daptomycin as Antibiotic Therapy for Staphylococcal Prosthetic Joint Infection

Andy O. Miller, MD,1,2 Celeste Russell, MPH2, Allina A. Nocon, PhD3, Geoffrey H. Westrich, MD4, Barry Brause, MD1,2 Michael M. Henry, MD1,2
1Infectious Diseases, Well Cornell Medicine, 2Infectious Diseases, Hospital for Special Surgery, 3Complex Joint Reconstruction Center, Hospital for Special Surgery, 4Orthopedic Surgery, Hospital for Special Surgery, New York,

Abstract

Background: Optimal antibiotic therapy for prosthetic joint infection (PJI) depends on patency, tissue durability, and cost-effectiveness. A FDA-approved antibiotic for the treatment of skin and soft tissue infections, but its role in treatment of PJI is less clear. We reviewed our experience with daptomycin (2012–2014), as surgical strategy and two-stage exchange, was switched to daptomycin, and two reached the primary endpoint after being changed to an alternative antibiotic regimen.

Methods

Retropective cohort study

Data source: Hospital for Special Surgery (HSS), Infection Database

Inclusion criteria:

2012–2014

241 patients with staphylococcal PJI

2

